Adavivint

Cas No.:	1467093-03-3
Chemical Name:	Adavivint
Synonyms:	N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide;Adavivint;lorecivivint;SM04690;42EK42WHI5;Adavivint [INN];Lorecivivint [USAN];Adavivint; SM04690;Adavivint (SM04690);GTPL9620;BCP30409;WHO 10389;s8761;DB14883;N-(5-{3-[7-(3-fluorophenyl)-1H-imidazo[4,5-c]pyridin-2-yl
SMILES:	FC1=C([H])C([H])=C([H])C(=C1[H])C1=C([H])N=C([H])C2=C1N=C(C1C3C([H])=C(C([H])=C([H])C=3N([H])N=1)C1C([H])=NC([H])=C(C=1[H])N([H])C(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)N2[H]
Formula:	C29H24FN7O
M.Wt:	505.5456
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Adavivint is a potent and selective inhibitor of canonical Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells.
In Vivo:	Adavivint (0.3 μg) enhances cartilage repair and protection in the rat acute cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) model[1].
In Vitro:	Adavivint (SM04690) is a potent and selective inhibitor of Wnt signaling, with an EC50 of 19.5 nM via a high-throughput TCF/LEF-reporter assay in SW480 colon cancer cells, and shows no effect on SV40 luciferase reporter. Adavivint enhances aggregation of human mesenchymal stem cells (hMSCs) with an EC50 of 10 nM. Adavivint (30 nM) protects chondrocytes from catabolic breakdown in vitro[1].